Chronic Myeloid Leukemia (CML) is a type of blood cancer that affects the bone marrow, where blood cells are produced. The development of targeted therapy for CML, specifically tyrosine kinase inhibitors (TKIs), has dramatically changed the outlook for patients with this disease.
Here are some applications of CML treatment:
TKIs: TKIs are medications that target the abnormal protein produced by the cancerous cells in CML. These drugs have revolutionized the Chronic Myeloid Leukemia Treatment, allowing most patients to achieve long-term remission and improving their quality of life. Examples of TKIs used for CML include imatinib, dasatinib, and nilotinib.
Bone marrow transplantation: For patients with advanced or refractory CML, bone marrow transplantation may be considered. This involves replacing the patient's bone marrow with healthy bone marrow from a donor.
Monitoring disease response: Regular monitoring of blood counts, bone marrow biopsy, and genetic testing can help assess the response to treatment and detect any signs of relapse.
Adherence to treatment: Because CML is a chronic disease, long-term adherence to treatment is critical to maintain remission. Patient education and support, as well as ongoing communication with healthcare providers, can help improve adherence and ensure the best possible outcome.
Research: Ongoing research is critical to developing new and more effective treatments for CML. Clinical trials are a key way that researchers are testing new therapies and approaches to treating this disease.
Read More:
https://cmitoc.blogspot.com/2023/02/revolutionary-targeted-therapy-for.html
